The efficacy and safety of the combination of anti-BRAF agent and MEK inhibitor in advanced melanoma patients with BRAF V600 mutation: A meta-analysis.

2015 ◽  
Vol 33 (15_suppl) ◽  
pp. e20006-e20006
Author(s):  
Changqing Xie ◽  
Basem Mourad Labib Mishriky ◽  
Phillip Chae ◽  
Prashanti Atluri
Keyword(s):  
Meta Analysis ◽  
Mek Inhibitor ◽  
Advanced Melanoma ◽  
Efficacy And Safety ◽  
Melanoma Patients ◽  
Braf V600 Mutation

Efficacy and safety of dabrafenib‐trametinib in the treatment of unresectable or metastatic melanoma with BRAF V600 mutation: A systematic review and network meta‐analysis

2020 ◽  
Author(s):  
Nathaly Garzón‐Orjuela ◽  
Laura Prieto‐Pinto ◽  
Pieralessandro Lasalvia ◽  
Daniel Herrera ◽  
Johanna Castrillón ◽  
...  
Keyword(s):  
Systematic Review ◽  
Metastatic Melanoma ◽  
Meta Analysis ◽  
Efficacy And Safety ◽  
Braf V600 Mutation

scholarly journals Analysis of BRAF and NRAS mutation status in advanced melanoma patients treated with anti-CTLA-4 antibodies: Association with overall survival?

2013 ◽  
Vol 31 (15_suppl) ◽  
pp. 9025-9025 ◽  
Author(s):  
Joanna Mangana ◽  
Simone M. Goldinger ◽  
Katja Schindler ◽  
Sima Rozati ◽  
Anna L. Frauchiger ◽  
...  
Keyword(s):  
Overall Survival ◽  
Braf Inhibitor ◽  
Mek Inhibitor ◽  
Advanced Melanoma ◽  
Braf V600e ◽  
Wild Type ◽  
Nras Mutation ◽  
Mutation Status ◽  
Mutational Status ◽  
Melanoma Patients

9025 Background: Ipilimumab and tremelimumab are human monoclonal antibodies against cytotoxic T-lymphocyte antigen-4 (CTLA-4). Ipilimumab was the first agent to show a statistically significant benefit in overall survival with durable-long-term responses for advanced melanoma patients both in first-and second-line setting. Up to date, there is no proven association between the BRAF-V600E mutation and the disease control rate (DCR) in response to Ipilimumab. Moreover, significantly shorter survival rates have been reported in patients harboring an NRAS mutation than in those without. This retrospective analysis was carried out to assess if BRAF (V600) and NRAS mutation status affects the clinical outcome of Ipilimumab-treated melanoma patients. Methods: This is a retrospective multi-center analysisof 71 patients, with confirmed BRAF and NRAS mutation status, treated with anti-CTLA-4 antibodies from December 2006 until August 2012. The cut-off for the estimation of overall survival was end of November 2012. Results: The median overall survival of BRAFV600/NRAS mutant patients (n=44) was 1,41 years compared with 2.67 years in BRAF/NRAS wild-type patients (n=27). Although this difference was not statistically significant there was a trend for improved survival in wild-type patients. Of the 71 patients analyzed, 56 received chemotherapy prior to Ipilimumab. In the BRAF/NRAS mutant cohort, 12 patients received Ipilimumab following either a BRAF- or a MEK- inhibitor. Of those 12 patients, 8 progressed and were unable to complete Ipilimumab. Of the 4 patients who completed 4 cycles of Ipilimumab, 2 were subsequently treated with a BRAF inhibitor. Furthermore out of the 71 patients, 8 patients received a BRAF or a MEK inhibitor after progression; 5 of them are still alive. Conclusions: This is the first retrospective study to evaluate the association of both BRAF and NRAS mutational status with the overall survival of Ipilimumab-treated patients. There was a trend towards an improved survival in the BRAF/NRAS wild-type subpopulation. Additional patients will be examined to foster these preliminary results.

Efficacy and safety of dabrafenib–trametinib in the treatment of unresectable advanced/metastatic melanoma with BRAF‐V600 mutation: A systematic review and network meta‐analysis

2019 ◽  
Vol 33 (2) ◽  
Author(s):  
Nathaly Garzón‐Orjuela ◽  
Laura Prieto‐Pinto ◽  
Pieralessandro Lasalvia ◽  
Daniel Herrera ◽  
Johanna Castrillón ◽  
...  
Keyword(s):  
Systematic Review ◽  
Metastatic Melanoma ◽  
Meta Analysis ◽  
Efficacy And Safety ◽  
Braf V600 Mutation

scholarly journals 1118P Retrospective analysis of safety in elderly BRAF V600 mutation-positive advanced melanoma patients treated with dabrafenib (D) and trametinib (T) and correlation with non-elderly patients

2020 ◽  
Vol 31 ◽  
pp. S753
Author(s):  
A. García-Castaño ◽  
I. González-Barrallo ◽  
V.E. Castellón Rubio ◽  
J. Medina Martínez ◽  
J.L. Manzano Mozo ◽  
...  
Keyword(s):  
Elderly Patients ◽  
Retrospective Analysis ◽  
Advanced Melanoma ◽  
Melanoma Patients ◽  
Braf V600 Mutation

scholarly journals Ipilimumab (Ipi) Exposure-Response (E-R) and Meta-Analysis of Overall Survival (Os) of Advanced Melanoma Patients (Pts)

2014 ◽  
Vol 25 ◽  
pp. iv381
Author(s):  
Y. Feng ◽  
D. Berman ◽  
T. Chen ◽  
E. Masson ◽  
A. Roy
Keyword(s):  
Overall Survival ◽  
Meta Analysis ◽  
Advanced Melanoma ◽  
Exposure Response ◽  
Melanoma Patients
Sign in / Sign up

Export Citation Format

Share Document